Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer combo therapy trial stopped early

NCT ID NCT03366766

First seen Feb 24, 2026 · Last updated Jun 17, 2026 · Updated 14 times

Summary

This study tested giving the immunotherapy drug nivolumab along with chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if this combination could shrink tumors enough to leave less than 10% cancer cells in the removed tissue. The trial was stopped early after enrolling only 14 participants, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Abington Hospital - Jefferson Health

    Abington, Pennsylvania, 19001, United States

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.